1. BEGIN File 414 to search Dialog Journal Name Finder.

2. EXPAND the journal name.

3. SELECT the appropriate “E” Reference number(s).

?B 414

File 414:Dialog Journal Name Finder(TM) 2007/Mar
       (c) 2007 Dialog

      Set  Items  Description
      ---  -----  -----------
?E   JN=PHARMA MARKETLETTER

Ref   Items  Index-term
E1        3  JN=PHARMA MARKETING SERVICE WIWO
E2        4  JN=PHARMA MARKETING SERVICE WSJ
E3       13 *JN=PHARMA MARKETLETTER
E4        3  JN=PHARMA MED
E5        2  JN=PHARMA MED.
E6        1  JN=PHARMA NANCY // BULL ASSOC DIPLOMES MICROBIOL
E7        1  JN=PHARMA NEWS // BALTIC
E8        1  JN=PHARMA NINE MONTHS ENDED SEP 2002 RESUL//BIO
E9        1  JN=PHARMA NINE MONTHS OF 2000 2001 RESULTS//PAN
E10       1  JN=PHARMA NINE MONTHS REPORT 2004 // SCHWARZ
E11       1  JN=PHARMA NINE MONTHS REPORT 2006 // SCHWARZ
E12       1  JN=PHARMA OL // J PHARM
E13       1  JN=PHARMA PATCH PRESS RELEASE
E14       1  JN=PHARMA PHYSIOL // CLIN EXP

Enter P or PAGE for more

?s e3
      S1      13  JN='PHARMA MARKETLETTER'

4. Enter REPORT S#/JOURNAL to display journal information in tabular form. The command will show the files that index this journal, the number of postings, and whether the database is bibliographic or fulltext.

5. Enter the line item numbers for the files you wish to begin searching.

6. Enter Yes (Y) to begin searching the files. Dialog will execute your search for the journal name.

?.REPORT S1/JOURNAL     

           DIALOG(R)File 414:Dialog Journal Name Finder(TM)
                   (c) 2007 Dialog  All rts. reserv.    

                      13 Journals  Available    

    Journal               File Number   Type   Record Count
------------------------------------------------------------
  1 PHARMA MARKETLETTER           148  FULLTEXT       24614
  2 PHARMA MARKETLETTER            16  FULLTEXT       22695
  3 PHARMA MARKETLETTER           149  FULLTEXT        7131
  4 PHARMA MARKETLETTER           993  FULLTEXT        6327
  5 PHARMA MARKETLETTER           992  FULLTEXT        5959
  6 PHARMA MARKETLETTER           991  FULLTEXT        4225
  7 PHARMA MARKETLETTER             9  FULLTEXT        3051
  8 PHARMA MARKETLETTER           990  FULLTEXT        1568
  9 PHARMA MARKETLETTER           994  FULLTEXT         138
 10 PHARMA MARKETLETTER           275  FULLTEXT           1
 11 PHARMA MARKETLETTER           211  BIBLIOGRAPHIC   2236
 12 PHARMA MARKETLETTER           286  BIBLIOGRAPHIC    499
 13 PHARMA MARKETLETTER            93  BIBLIOGRAPHIC      1

Enter item number(s), P for next page, or EXIT to end 
Report:
?.1,2,7

Selected item(s): 1,2,7
Items from file(s): 9, 16, 148 

Enter YES to save items and begin searching these files,
P for next page, or EXIT to end Report:
?Y 

Temp SearchSave "TC164" stored
1 Select Statement, 1 Search Term(s)
SearchSave TC164

1 SearchSave(s),  1 Search Term(s)
Leaving Report/JOURNAL...

7. Dialog created Set 1 (S1) with the executed search on the journal name.

8. Now combine S1 with additional criteria, such as a publication year (PY=) range. The colon indicates a range of years.

9. Combine with keywords using truncation with the “?”. The proximity connector (S) finds words in the same paragraph.

10. REMOVE DUPLICATES (RD) when searching more than one database.

Tip: An additional optional command allows you to determine if a particular journal is in fulltext: S S#/FULLTEXT. See the Bluesheet for Limit features available.

SYSTEM:OS  - DIALOG OneSearch
  File   9:Business & Industry(R) Jul/1994-2007/Dec 20
         (c) 2007  The Gale Group
  File  16:Gale Group PROMT(R) 1990-2007/Dec 21
         (c) 2007 The Gale Group
  File 148:Gale Group Trade & Industry DB 1976-2007/Dec 19
         (c)2007 The Gale Group

      Set  Items  Description
      ---  -----  -----------
      S1   62988  JN="PHARMA MARKETLETTER"

?S   S1 AND PY=2007:2008
           62988  S1
         2417136  PY=2007 : PY=2008
      S2   14869  S1 AND PY=2007:2008

?S S2 AND  KINASE?(S)INHIBIT?
           14869  S2
           12669  KINASE?
          177168  INHIBIT?
            7867  KINASE?(S)INHIBIT?
      S3      59  S2 AND KINASE?(S)INHIBIT?

?RD
      S4      51  RD  (unique items)

11. TYPE a sampling of records FROM EACH of the databases in Format 8 to view titles, publication dates, word counts and descriptors.

Add FROM EACH to the end of the TYPE command to see one or more records from each database in the search. Note the word counts indicating the journal is in fulltext.

To select the appropriate record number, look at the range of records in the TYPE command (e.g., 4/8/2).

?T S4/8/1 FROM EACH

  4/8/1  (Item 1 from file: 9) 
        DIALOG(R)File 9: Business & Industry(R)
        (c) 2007 The Gale Group. All rights reserved.

        04345159  Supplier Number: 172187957 
  Merck & Co suspends enrollment in trial of lead Aurora 
kinase drug. 

    November 26, 2007 
  Word Count: 170 
  Company Names: MERCK & COMPANY INC; VERTEX PHARMACEUTICALS 
INC 
  Industry Names: Pharmaceutical 
  Product Names: Pharmaceutical preparations (283400)

  4/8/22  (Item 1 from file: 16) 
DIALOG(R)File 16: Gale Group PROMT(R)
(c) 2007 The Gale Group. All rights reserved.

14575987    Supplier Number: 172652894 (USE FORMAT 7 FOR  
FULLTEXT) 

Cancer drugs targeting ErbB pathway generate $5B sales in 
nine months of  2007. 
Dec 10 , 2007 
Word Count: 649 
Publisher Name: Marketletter Publications Ltd. 
Descriptors: *Cancer--Care and treatment 
Product Names: *8000432 (Cancer Therapy) 
Industry Names: INTL (Business, international ) 
SIC Codes: 8000 (HEALTH SERVICES ) 

NAICS Codes: 621 (Ambulatory Health Care Services ) 

12. TYPE selected record(s) in Format 7, which gives you the Bibliographic Citation and the text.

Note: Part of this record is omitted from the display.

?T S4/7/22 
      4/7/22 (Item 1 from file: 16) 
      DIALOG(R)File 16: Gale Group PROMT(R)
      (c) 2007 The Gale Group. All rights reserved.
      
      14575987    Supplier Number: 172652894 (THIS IS THE
FULLTEXT) 
      
      Cancer drugs targeting ErbB pathway generate $5B sales
      in nine months of  2007. 
            Pharma Marketletter , p NA 
        Dec 10 , 2007 
            
            Text:
  Six ErbB (EGFr/HEr2)-pathway inhibitors, marketed for 
the treatment of several major solid tumor indications,
generated global sales of $4.96 billion in the first nine 
months of 2007, almost reaching the $5.16 billion total 
revenues of these agents in 2006, according to New 
Medicine's Oncology KnowledgeBASE.

  Despite this unprecedented market success and the 
acceptance of targeted therapies in oncology practice, 
it notes, many challenges remain unfulfilled. One key 
problem of currently-approved agents is the relatively 
marginal benefits they provide; median progression-free 
survival (PFS) and overall survival (OS) are extended 
only by a few months. However, aggressive efforts to 
overcome current limitations are providing unique 
opportunities in this field.

       Currently, all targeted therapeutics, both approved 
and novel, are under evaluation almost exclusively in 
combination with approved cytotoxic agents. Because cytotoxics 
remain the treatment mainstay for adjuvant, neoadjuvant and 
advanced/metastatic disease, opportunities still exist for 
the development of more effective, less toxic alternatives.

       Multi-targeted agents in development
       Targeted therapeutics are also under investigation 
in combination with each other, in efforts to simultaneously 
inhibit additional or compensating pathways, or to maximize 
effectiveness against a single target by combining drugs 
acting by different mechanisms, eg, receptor tyrosine kinase 
(RTK) inhibitors and monoclonal antibodies, against the same 
target. Also, multi-targeted inhibitors are in development 
against different targets in the same or different pathways 
hypothesized to act in concert in malignancy.

       The commercial success of the ErbB inhibitors, as well 
as other targeted anticancer agents has stimulated R&D in 
this field. More than 370 drugs have entered clinical trials, 
with many having already reached Phase II clinical (n=183) or 
Phase III (n=43) stages of development. In addition, hundreds 
of agents are in preclinical development. Their mechanisms of 
action are wide ranging, targeting some of the more than 1,000 
different molecular markers implicated in malignancy.

       Molecularly-targeted agents in development are ushering 
in the age of personalized medicine. There is pressing need for 
better diagnostic, theragnostic, prognostic, pharmacogenomic 
and disease monitoring methodologies for patient selection and 
optimized treatment.. . . .

COPYRIGHT 2007 Marketletter Publications Ltd.

COPYRIGHT 2007 Gale Group